STOCK TITAN

Iambic Therapeutics (IAM) Financials

IAM NASDAQ
Market Cap $621.4M as of Nov 20, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m no full year of net income reported yet
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Key Financial Metrics

Export CSV

No financial data available for Iambic Therapeutics, Inc..

Financial data is sourced from SEC filings. This company may not have filed yet or may trade on a non-US exchange.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Sagimet Biosciences Inc. SGMT FY2025 N/A -$51.0M N/A $648.0M —
Kura Oncology, Inc. KURA FY2025 $67.5M -$278.7M N/A $634.9M 75/100
Janux Therapeutics, Inc. JANX FY2025 $10.0M -$113.6M N/A $616.7M 71/100
Arbutus Biopharma Corporation ABUS FY2025 $14.1M -$33.5M N/A $616.2M 66/100
Olema Oncology, Inc. OLMA FY2025 N/A -$162.5M N/A $615.0M —
Back to top